EXHIBIT 10.58

CONFIDENTIAL TREATMENT REQUESTED

AMENDMENT NO. 1 TO SUBLICENSE AGREEMENT

This Amendment is made as of the 30th day of November 1998, between TITAN
PHARMACEUTICALS, INC., a corporation organized under the laws of the State of
Delaware and having its principal offices at 400 Oyster Point Blvd., Suite 505,
South San Francisco, CA 94080 U.S.A. (hereinafter “TITAN”), and NOVARTIS PHARMA
A.G., a corporation organized under the laws of Switzerland and having its
principal offices at Lichtstrasse 35, CH 4002, Basel, Switzerland (hereinafter
“NOVARTIS”).

WITNESSETH

WHEREAS, the parties have entered into that certain Sublicense Agreement,
effective as of November 20. 1997 (the “Principal Agreement”), whereby, among
other things, TITAN granted to NOVARTIS an exclusive sublicense relating to a
compound known as Iloperidone; and

WHEREAS, by this Amendment the parties desire to amend the Principal Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants
contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, and intending to be legally bound,
the pasties hereto agree as follows:

1. The term “Agreement”, as used and defined in the Principal Agreement, shall
mean the Principal Agreement as amended by this Amendment. Terms defined in the
Principal Agreement and not otherwise defined herein are used herein as defined
in the Principal Agreement.

2. Except as otherwise provided herein, the terms and provisions of the
Principal Agreement shall be unchanged and shall continue in full force and
effect.

3. Appendix A to the Principal Agreement is hereby amended in its entirety to be
and read in the form attached as Appendix A to this Amendment.

4. This Amendment may be executed in any number of counterparts, each of which
should be deemed to be an original, but all of which together shall constitute
one and the same Amendment.

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED

 

IN WITNESS WHEREOF, the parties hereby intending to be legally bound have caused
this Amendment to be executed and delivered by their proper and duly authorized
officers as of the day and year first above written.

 

NOVARTIS PHARMA A.G. TITAN PHARMACEUTICALS, INC. By:

/s/ Olivier Bassi    /s/ James S. New

By:

/s/ Louis R. Bucalo

Date:  August 27, 1999 Date:  November 30, 1998

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED

 

APPENDIX A

PATENTS AND PATENT APPLICATIONS (PER SECTION 1.17)

(As amended per Amendment No. 1 to Sublicense Agreement)

 

Country

  

Patent Appl. No.

  

Filing Date

  

Type

  

Status

  

Patent No.

  

Issue Date

  

Expiration

Date

                                                              

****

 

**** CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED

 

Country

 

Patent Appl. No.

 

Filing Date

 

Type

 

Status

 

Patent No.

 

Issue Date

 

Expiration

Date

                                         

****

 

**** CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED

 

Country

 

Patent Appl. No.

 

Filing Date

 

Type

 

Status

 

Patent No.

 

Issue Date

 

Expiration

Date

                                         

****

 

**** CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.